Western blot analysis showed that Irisin treatment increased the ratio of MAP1LC3B-II/I and SQSTM1 degradation and decreased the expression of NLRP3 inflammasome components and pyroptosis-related markers compared with that in the CKD group (Fig. 7J, K). This evidence concerns the gene MAP1LC3B and chronic kidney disease.